AvenCell Europe GmbH

General information
AvenCell Europe GmbH
Tatzberg 47
01307 Dresden, Saxony
Germany

Contact person: Andrew Schiermeier, CEO
Company main phone: +49 (351) 44664500
Website:  avencell.com
Year founded:2011
Source of foundation:Independent foundation
Corporate description / mission:
AvenCell Europe GmbH has a broad pipeline of next generation immunotherapy product candidates in pre-clinical and clinical development for the treatment of hematological malignancies as well as solid tumors. The company's lead clinical stage assets GEM333, a T cell engaging bispecific antibody (TCE) with binding specificity to CD33 against relapsed/refractory acute myeloid leukemia, and GEM3PSCA, a TCE with binding specificity to PSCA for the treatment of metastatic castrate-resistant prostate cancer as well as pancreatic, breast, bladder, renal and non-small cell lung cancer, are currently in Phase I studies. GEM3PSCA is globally partnered with Bristol-Myers Squibb.
State of ownership: Private / independent
Headquarters: Yes
Remarks on ownership / listings
Formerly GEMoaB GmbH
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Antibodies
  • Immunotherapy
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • R&D
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Physicians / doctors
Summary Products / Services / Technologies
Description of products:
GEM333
GEM3PSCA
UniCAR-T-PSMA
UniCAR-T 3, etc.
Technology used:
UniCAR, RevCAR and TCE
Collaborations & Clients
Partnering strategy / collaborations:
Intellia Therapeutics
Blackstone Lifesciences
© 2023 Biotechgate by Venture Valuation
X